Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITRO-DUR vs ISORDIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a prodrug that is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylyl cyclase, increasing c GMP, leading to vasodilation primarily in veins and arteries.
Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.
Prophylaxis and treatment of angina pectoris due to coronary artery disease,Heart failure (IV formulation),Hypertensive crisis (IV formulation),Anal fissures (topical ointment)
Angina pectoris (prophylaxis and acute treatment),Heart failure (off-label: adjunctive treatment in acute myocardial infarction)
Transdermal: Initial 0.2-0.4 mg/h applied once daily, titrate to 0.4-0.8 mg/h; maximum 0.8 mg/h. Remove for 10-12 hours daily to prevent tolerance.
Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.
2–3 minutes (nitroglycerin); prolonged to ~30 minutes for active metabolites. Clinical context: Requires frequent dosing or continuous administration for sustained effect.
Terminal half-life: 1–4 hours (isosorbide dinitrate); clinical context: short duration requires frequent dosing or sustained-release formulations.
Metabolized by glutathione S-transferases (GSTs) in the liver and erythrocytes, producing glycerol dinitrate and nitrite ions.
Primarily hepatic via glutathione-organic nitrate reductase; also undergoes denitration to active metabolites (isosorbide-2-mononitrate and isosorbide-5-mononitrate).
Primarily renal (>80% as inactive metabolites; <1% unchanged nitroglycerin). Minor biliary/fecal elimination.
Renal: 80% as inactive metabolites; biliary/fecal: 20% as conjugates.
~60% (mainly to albumin).
~28% bound to albumin.
~3 L/kg (extensive tissue distribution).
2–4 L/kg, indicating extensive tissue distribution.
Transdermal: ~70% (relative to IV). Oral: <10% (extensive first-pass metabolism).
Sublingual: ~40–60% (first-pass bypassed); oral: <30% due to extensive first-pass hepatic metabolism.
No dose adjustment needed for any degree of renal impairment.
No specific GFR-based dose adjustments are recommended; however, caution is advised in severe renal impairment due to potential accumulation of metabolites.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Use with caution, consider dose reduction by 25-50% due to reduced metabolism. Child-Pugh Class C: Avoid use or use minimal effective dose (e.g., 0.2 mg/h) with close monitoring.
In Child-Pugh class A: no adjustment. Child-Pugh class B and C: reduce dose by 50% and monitor for hypotension.
Safety and efficacy not established in pediatric patients; no standard dosing guidelines.
Isosorbide dinitrate: not recommended for use in children due to lack of safety and efficacy data; no established pediatric dosing guidelines.
Start at low end of dosing range (0.2 mg/h), titrate slowly, monitor for hypotension and dizziness. Increased sensitivity due to age-related vascular changes; may require extended nitrate-free interval (e.g., 12-14 hours).
Elderly patients may have increased sensitivity to hypotension. Initiate with lowest doses (e.g., 5 mg orally twice daily) and titrate slowly. Monitor blood pressure and orthostatic changes.
Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension.
Do not use in patients with erectile dysfunction medications (PDE-5 inhibitors) due to risk of severe hypotension.
Hypotension, especially in hypovolemic patients; tolerance with chronic use; paradoxical bradycardia and increased angina; exacerbate hypertrophic cardiomyopathy; avoid abrupt discontinuation.
Hypotension (especially with volume depletion or alcohol),Tolerance with prolonged use (intermittent dosing recommended),Exacerbation of angina upon abrupt withdrawal,Use cautiously in hypertrophic cardiomyopathy
Concomitant use with PDE-5 inhibitors; severe anemia; increased intracranial pressure; hypersensitivity to nitroglycerin; acute circulatory failure; constrictive pericarditis; pericardial tamponade.
Hypersensitivity to nitrates,Concurrent use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil),Severe anemia,Increased intracranial pressure (head trauma, cerebral hemorrhage),Acute circulatory failure (shock, vascular collapse)
Avoid alcohol, as it can enhance hypotensive effects. No specific food restrictions, but high-fat meals may delay absorption of nitroglycerin if administered orally; transdermal route is less affected.
Avoid excessive alcohol consumption. No specific food interactions; however, high-fat meals may delay absorption of oral formulations. Maintain consistent dietary habits to minimize variations in drug effects.
FDA Pregnancy Category C. First trimester: Animal studies show fetal harm, but no adequate human studies; potential risk cannot be ruled out. Second and third trimesters: Possible fetal bradycardia, hypotension, and reduced placental perfusion; avoid near term due to risk of maternal hypotension and fetal distress.
Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. It should be used during pregnancy only if clearly needed. Potential fetal risks include hypotension and reduced uteroplacental perfusion, particularly in the first trimester. Second and third trimester risks are theoretical due to maternal hemodynamic changes. Avoid use near term due to risk of neonatal methemoglobinemia. FDA pregnancy category C.
Excreted in breast milk; M/P ratio not established. Use with caution, monitor infant for hypotension or methemoglobinemia; consider pump and discard if high doses used.
Excretion in human milk is unknown. Due to potential for serious adverse reactions in nursing infants (e.g., methemoglobinemia), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio not reported.
No specific dose adjustments recommended; however, increased plasma volume may reduce drug concentrations; titrate to effect, avoid hypotension to maintain placental perfusion.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance; however, no specific dose adjustments are established. Use lowest effective dose with careful titration to avoid hypotension. Initiate with 5-10 mg sublingual for acute episodes; for prophylaxis, 10-40 mg orally every 6 hours. Monitor for excessive hypotension.
NITRO-DUR (nitroglycerin) transdermal patch is used for angina prophylaxis, not acute attacks. Apply to hairless area, avoid chest if possible to prevent interference with defibrillation. Rotate sites daily to prevent tolerance; remove patch for 10-12 hours daily to maintain nitrate-free interval. Contraindicated with PDE5 inhibitors (sildenafil, tadalafil, vardenafil) due to risk of severe hypotension. Monitor for hypotension, reflex tachycardia, headache.
Isordil (isosorbide dinitrate) is a nitrate vasodilator used for angina prophylaxis. Sublingual formulation provides rapid onset for acute attacks; oral sustained-release is for chronic prophylaxis. Tolerance develops with continuous exposure; use a daily nitrate-free interval of 10-12 hours. Avoid use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) due to severe hypotension. Monitor for headache, hypotension, and reflex tachycardia.
Apply patch once daily to clean, dry, hairless skin on upper arm, chest, or back.,Remove old patch before applying new one.,Keep patch on for 12-14 hours then remove for 10-12 hours to prevent tolerance.,Do not use during acute angina attack; use sublingual nitroglycerin instead.,Avoid alcohol and erectile dysfunction drugs (Viagra, Cialis, Levitra) while using this patch.,Common side effects: headache, dizziness, flushing. Report severe headache or fainting.,Do not stop abruptly; may cause rebound angina.
Take sublingual isordil at the first sign of an angina attack; sit down before using to avoid dizziness.,For chronic prophylaxis, take as prescribed; do not skip doses to maintain the nitrate-free interval.,Avoid alcohol as it can increase the risk of hypotension and dizziness.,Report any severe headaches, worsening chest pain, or fainting to your healthcare provider immediately.,Never take erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on isordil.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITRO-DUR vs ISORDIL, answered by our medical review team.
NITRO-DUR is a Nitrate Vasodilator that works by Nitroglycerin is a prodrug that is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylyl cyclase, increasing c GMP, leading to vasodilation primarily in veins and arteries.. ISORDIL is a Nitrate Vasodilator that works by Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITRO-DUR and ISORDIL depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITRO-DUR is: Transdermal: Initial 0.2-0.4 mg/h applied once daily, titrate to 0.4-0.8 mg/h; maximum 0.8 mg/h. Remove for 10-12 hours daily to prevent tolerance.. The standard adult dose of ISORDIL is: Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITRO-DUR and ISORDIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITRO-DUR is classified as Category C. FDA Pregnancy Category C. First trimester: Animal studies show fetal harm, but no adequate human studies; potential risk cannot be ruled out. Second and third trimesters: Possible . ISORDIL is classified as Category C. Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.